滤泡性淋巴瘤(FL)是北美最常见的惰性非霍奇金淋巴瘤(NHL)。由于疾病的异质性,治疗选择从观察到积极治疗或干细胞移植,或者两者兼而有之。尽管治疗的进步改善了结果,这种疾病在很大程度上仍然无法治愈。在加拿大,对于FL的一线治疗没有统一的国家指南;省级指南各不相同,主要基于资金.因此,需要由加拿大血液学家支持的基于证据的国家治疗指南,以确保FL患者能够公平地获得最佳可用护理。来自加拿大各地的专家组制定了国家循证治疗指南,为医疗保健专业人员提供有关FL一线管理的明确指导。文献系统回顾的结果根据现有证据提出了共识建议。
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL) in North America. Because of the heterogeneity of the disease, treatment options vary from observation to aggressive therapies or stem cell transplantation, or both. Although advances in treatment have improved outcomes, the disease remains largely incurable. In Canada, no unified national
guideline exists for the front-line treatment of FL; provincial
guidelines vary and are largely based on funding. There is therefore a need for evidence-based national treatment
guidelines that are supported by Canadian hematologists to ensure that patients with FL have equitable access to the best available care. A group of experts from across Canada developed a national evidence-based treatment
guideline to provide health care professionals with clear guidance on the first-line management of FL. Results of a systematic review of the literature are presented with
consensus recommendations based on available evidence.